Cingulate Inc.

Contributing Author

Recent Articles by Cingulate Inc.

Oct-28	Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control CING GlobeNewswire
Oct-23	Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting CING GlobeNewswire
Oct-14	FDA Accepts Cingulate's New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date CING GlobeNewswire
Sep-17	Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment CING GlobeNewswire
Aug-19	Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights CING GlobeNewswire
Aug-15	Cingulate Provides Management Team Update CING GlobeNewswire
Aug-06	Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301 CING GlobeNewswire
Jul-29	Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301 CING GlobeNewswire
Jul-09	Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application CING GlobeNewswire
May-20	Efficacy Results Announced from Cingulate's Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD CING GlobeNewswire
May-14	FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301 CING GlobeNewswire
May-08	Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets CING GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.